Atnaujinkite slapukų nuostatas

Good Pharma: The Public-Health Model of the Mario Negri Institute [Kietas viršelis]

3.00/5 (2 ratings by Goodreads)
,
  • Formatas: Hardback, 282 pages, aukštis x plotis: 235x155 mm, weight: 5738 g, XVIII, 282 p., 1 Hardback
  • Išleidimo metai: 01-Jul-2015
  • Leidėjas: Palgrave Macmillan
  • ISBN-10: 1137388331
  • ISBN-13: 9781137388339
Kitos knygos pagal šią temą:
Good Pharma: The Public-Health Model of the Mario Negri InstituteDidesnis paveikslėlis
  • Formatas: Hardback, 282 pages, aukštis x plotis: 235x155 mm, weight: 5738 g, XVIII, 282 p., 1 Hardback
  • Išleidimo metai: 01-Jul-2015
  • Leidėjas: Palgrave Macmillan
  • ISBN-10: 1137388331
  • ISBN-13: 9781137388339
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9781137388339.html
Raktažodžiai:
Drawing on key concepts in sociology and management, this history describes a remarkable institute that has elevated medical research and worked out solutions to the troubling practices of commercial pharmaceutical research. Good Pharma is the answer to Goldacre's Bad Pharma, ethical research without commercial distortions that mislead doctors and patients. This extended case history of the Mario Negri Institute describes how a brilliant young researcher, Silvio Garattini, and a boldly imaginative philanthropist, Mario Negri, conceived of an independent, ethics-based research institute to develop better medicines for patients. It may sounds obvious; yet patent-based research usually develops minor variations. This book describe the Institute's influence on founding the WHO Essential Medicines List, nurturing the Cochrane Collaboration, and reforming European regulations to reduce commercial influences and increase transparency. The Mario Negri model for pharmacological research and policy offers an alternative to today's costly, wasteful drug development with few benefits for patients. A revolution is needed.

Recenzijos

Good pharma is a fascinating story and a must read for all those who believe that something is not right about the way we incentivise medical research today. Both laypersons and specialists in the field will find something to think about in a book that is full of delectable nuggets of information interspersed in the story of Silvio Garattini and the Mario Negri Institute. (Amit Sengupta, Indian Journal of Medical Ethics, August, 2016)

By offering a sociological perspective on the drug development process, this book presents an alternative perspective to mainstream pharmaceutical drug production focused on patenting and profit while ignoring public-health needs. The book shows how personal life events and experiences collided to lead to the founding of the institute. a welcome addition to the sociology of health and medicine and would likely appeal to those interested in critical perspectives of pharmaceuticals, health and the regulation of clinical trials. (Shadreck Mwale, Sociology of Health & Illness, June, 2016)

The authors document what they see as the generalizable best practices of this pharmacological research institution, which is based in Milan and has centers in two other Italian cities. Some readers may already be familiar with the litany of complaints about the pharmaceutical industry, as well as the proposed best practices chronicled in Good Pharma. Even for them, the book may be worth reading. (Jennifer E. Miller, Health Affairs, Vol. 34 (12), 2015)

Good Pharma tells the story from 1961 to present of the origins and development of the Instituto di Ricerche Farmacologiche Mario Negri, named after its endower, a Milanese jeweller-philanthropist. Good Pharma is worth reading and digesting as it documents how the Negri model has produced some outstanding successes, such as the GISSI trials, and makes a strong case for viewing pharmacological research as a long-term risky investment. (Drug and Therapeutics Bulletin of Navarre, Vol. 23 (2), 2015)

Daugiau informacijos

"As Light and Maturo write, the Italy-based pharmacological research institution prides itself on "patient-oriented" research rather than a "patent-oriented" model ... . In some ways the Mario Negri approach is not revolutionary: the institute competes for the same grants and contracts as other research organizations. It studies the same types of diseases as other researchers, including breast cancer, epilepsy, and dementia. But it departs from the norm by refusing to pursue patents on the drugs and methods it develops and by pledging open-source sharing of its research data. The institute has also made a commitment not to drop a drug candidate because its profit potential is too low. It is an approach that would have prevented the tragedy of the vaccine for Ebola being unavailable because it sat undeveloped for 10 years due to its perceived unprofitability. The Institute won't allow industry representatives to ghost-write journal articles for its researchers, and it structures clinical trials to include practicing physicians on the research team, an approach it believes will ensure its research has treatment relevancy." (Fran Quigley, Professor of Law, Indiana University, USA) "...combines a devastating critique of the pervasive harms of patent-driven medical research by the pharmaceutical industry with a compelling account of an alternative..." (Erik Olin Wright, Vilas Distinguished Professor, Wisconsin, Past-President, American Sociological Association) "...a bright light on a remarkable approach to conducting pharmacological research in the public interest...research motivated by a social mission centered on compassion for and responsibility to the vulnerable, sick and suffering." (Arthur L. Caplan, Mitty Professor of Bioethics, New York University)
List of Illustrations
ix
Foreword xi
Preface and Acknowledgments xv
List of Abbreviations
xvii
Introduction: Beneficence through Principled Research for Patients 1(18)
Part I Developing a Research Institute for Society
1 Origins and an American Vision for an Ethical, Independent Research Institute
19(16)
2 The Formative Years---Leadership, Culture, and Organization
35(26)
3 Expansions to New Campuses and Integrated Research
61(30)
4 Educating the Public and Future Researchers
91(28)
Part II Reconceiving the Aims of Pharmacological Research
5 From Measuring Environmental Toxins to Drugs as Contaminants
119(14)
6 Pioneering Ethical Trials for Integrated Research
133(28)
Part III Promoting Good Science for Better Medicines
7 Science-Based Initiatives against Dangerous or Useless Drugs
161(18)
8 International Campaigns against Harmful Regulations and Practices
179(18)
9 Good Science for Good Pharma---A Public-Health Model
197(22)
Appendix 1 Psychotropic Drugs: An Example of Mario Negri Research in the 1960s 219(4)
Appendix 2 Published Trials by the Mario Negri Institute since 2000 223(26)
Notes 249(26)
Index 275
Donald W. Light is Professor of Comparative Health Policy at Rowan University, USA and has published widely in major medical and sociological journals on ethical as well as sociological issues. Recently, he served as the Lokey Visiting Professor at Stanford University, USA and as a Visiting Fellow at Harvard University, USA.  

Antonio Maturo is Associate Professor of Sociology of Health at Bologna University, Italy and Visiting Professor at Brown University, USA. He has published several books in Italian and he has edited The Medicalization of Life (2009, with P. Conrad) and The Medicine of Emotions and Cognitions (2012, with K. Barker).